(19)
(11) EP 2 691 534 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.10.2017 Bulletin 2017/41

(45) Mention of the grant of the patent:
26.07.2017 Bulletin 2017/30

(21) Application number: 12771223.0

(22) Date of filing: 22.02.2012
(51) International Patent Classification (IPC): 
G01N 33/53(2006.01)
G01N 33/68(2006.01)
 G01N 33/574(2006.01)
G01N 33/74(2006.01)
(86) International application number:
PCT/US2012/026141
(87) International publication number:
WO 2012/141792 (18.10.2012 Gazette 2012/42)

(54)

ADIPONECTIN RECEPTOR C-TERMINAL FRAGMENTS (CTF)-IMMUNOGLOBULIN

IMMUNOGLOBULIN MIT ADIPONEKTIN-REZEPTOR-C-TERMINAL-FRAGMENTEN (CTF)

FRAGMENTS C-TERMINAUX (CTF) DE RÉCEPTEUR D'ADIPONECTINE-IMMUNOGLOBULINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 11.04.2011 US 201161445103 P

(43) Date of publication of application:
05.02.2014 Bulletin 2014/06

(73) Proprietor: Siemens Healthcare Diagnostics Inc.
Tarrytown, NY 10591-5098 (US)

(72) Inventor:
  • PUGIA, Michael
    Granger, IN 46530 (US)

(74) Representative: Schweitzer, Klaus et al
Plate Schweitzer Zounek Patentanwälte Rheingaustrasse 196
65203 Wiesbaden
65203 Wiesbaden (DE)


(56) References cited: : 
EP-A1- 1 870 710
WO-A2-2005/001061
US-A1- 2010 143 958
 WO-A1-2010/123720
US-A1- 2008 221 305
US-A1- 2010 143 958
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).